Calcium alginate gel: a biocompatible and mechanically stable polymer for endovascular embolization.

The development and optimization of calcium alginate for potential use in endovascular occlusion was investigated by testing its in vitro and in vivo mechanical stability and biocompatibility. The compressive resistance, rheology, and polymer yield of reacted alginate, and the polymer viscosity of unreacted alginate, were assessed. Biocompatibility was tested by injecting calcium alginate into the kidney capsule of rats. The reactivity of alginates with various structures and levels of purity were compared visually and histologically. Results suggest that calcium alginate is a biocompatible and mechanically stable gel for endovascular applications. Purified alginates exhibited compressive strength of 22 kPa and above at 40% compression, with no significant loss in elasticity. Purified alginate strength was significantly higher than that of crude alginates (p < 0.08). Purified alginates also exhibited significantly lower tissue reaction than crude alginates (p < 0.05). Of the alginates tested, purified high guluronic acid alginates (PHG) exhibited optimal strength and polymer yield, increased biocompatibility, and decreased viscosity. Clinical embolization treatments may be improved with the development of stable and biocompatible polymers such as calcium alginate. Possible uses of improved endovascular polymers include treating arteriovenous malformations (AVMs), aneurysms, blood flow to tumors, and vascular hemorrhaging.

[1]  Y. Ikada,et al.  Non-adhesive cyanoacrylate as an embolic material for endovascular neurosurgery. , 2000, Biomaterials.

[2]  I. Trail,et al.  Cytotoxicity of Cyanoacrylate Adhesives to Cultured Tendon Cells , 1999, Journal of hand surgery.

[3]  T. Chandy,et al.  Evaluation of modified alginate-chitosan-polyethylene glycol microcapsules for cell encapsulation. , 1999, Artificial organs.

[4]  R. Price,et al.  Experimental evaluation of cellulose acetate NF and ethylene-vinyl alcohol copolymer for selective arterial embolization. , 1999, Journal of vascular and interventional radiology : JVIR.

[5]  T. Massoud,et al.  Transvenous retrograde nidus sclerotherapy under controlled hypotension (TRENSH): a newly proposed treatment for brain arteriovenous malformations--concepts and rationale. , 1999, Neurosurgery.

[6]  T. Tamiya,et al.  Embolization of cerebral arteriovenous malformations with cellulose acetate polymer: a clinical, radiological, and histological study. , 1999, Neurosurgery.

[7]  W. Castañeda-Zúñiga,et al.  A simplified arteriovenous malformation model in sheep: feasibility study. , 1999, AJNR. American journal of neuroradiology.

[8]  A. Biondi,et al.  Major complications of percutaneous embolization of skull-base tumors. , 1999, AJNR. American journal of neuroradiology.

[9]  Y. Ikada.  Application of biomedical engineering to neurosurgery. , 1998, Neurologia medico-chirurgica.

[10]  H. Vinters,et al.  Nonadhesive liquid embolic agent for cerebral arteriovenous malformations: preliminary histopathological studies in swine rete mirabile. , 1998, Neurosurgery.

[11]  E. Edelman,et al.  The biologic effects of growth factor-toxin conjugates in models of vascular injury depend on dose, mode of delivery, and animal species. , 1998, Journal of pharmaceutical sciences.

[12]  J. Deveikis.  Endovascular therapy of intracranial arteriovenous malformations. Materials and techniques. , 1998, Neuroimaging clinics of North America.

[13]  G. Joseph,et al.  Transvenous embolization as the primary therapy for arteriovenous fistulas of the lateral and sigmoid sinuses. , 1998, AJNR. American journal of neuroradiology.

[14]  Takuyu Taki,et al.  TRANSPLANTATION OF XENOGENEIC CELLS SECRETING β-ENDORPHIN FOR PAIN TREATMENT: ANALYSIS OF THE ABILITY OF COMPONENTS OF COMPLEMENT TO PENETRATE THROUGH POLYMER CAPSULES. , 1997, Cell transplantation.

[15]  J. H. Lee,et al.  Development and characterization of an alginate-impregnated polyester vascular graft. , 1997, Journal of biomedical materials research.

[16]  D. Craig,et al.  Characterization of the Block Structure and Molecular Weight of Sodium Alginates , 1997, The Journal of pharmacy and pharmacology.

[17]  Y. Ikada,et al.  Nontoxic embolic liquids for treatment of arteriovenous malformations. , 1997, Journal of biomedical materials research.

[18]  G. Klöck,et al.  Biocompatibility of mannuronic acid-rich alginates. , 1997, Biomaterials.

[19]  P. Vos,et al.  Effect of the alginate composition on the biocompatibility of alginate-polylysine microcapsules , 1997 .

[20]  P. De Vos,et al.  Improved biocompatibility but limited graft survival after purification of alginate for microencapsulation of pancreatic islets , 1997, Diabetologia.

[21]  M. Červinka,et al.  Hydrogels in endovascular embolization. VI. Toxicity tests of poly(2-hydroxyethyl methacrylate) particles on cell cultures. , 1988, Biomaterials.

[22]  T. Nose,et al.  Embolic materials for endovascular treatment of cerebral lesions. , 1997, Journal of biomaterials science. Polymer edition.

[23]  M. Diksic,et al.  The Efficacy of Retrograde Infusion with LY231617 in a Rat Middle Cerebral Artery Occlusion Model , 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[24]  G. Duckwiler,et al.  Laboratory simulations and training in endovascular embolotherapy with a swine arteriovenous malformation model. , 1996, AJNR. American journal of neuroradiology.

[25]  N. Obuchowski,et al.  The safety and effectiveness of brain arteriovenous malformation embolization using acrylic and particles: the experiences of a single institution. , 1995, Neurosurgery.

[26]  R. Browne,et al.  Subperiosteal behaviour of alginate and cellulose wound dressing materials. , 1995, Biomaterials.

[27]  G. Skjåk‐Braek,et al.  An immunologic basis for the fibrotic reaction to implanted microcapsules. , 1991, Transplantation proceedings.

[28]  R F Spetzler,et al.  A proposed grading system for arteriovenous malformations. , 1986, Journal of neurosurgery.